Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

Summary

This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and ARM B: immediate surgery with curative intent.

Timeline

Start

2016-01

Primary completion

2018-09

Completion

2021-01

Drugs

Indications